We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Issues Delegated Act on Situations Warranting Postmarketing Studies
EMA Issues Delegated Act on Situations Warranting Postmarketing Studies
May 8, 2014
Sponsors that use surrogate endpoints, such as biomarkers, in confirmatory cancer trials may need to provide postmarketing data to the European Medicines Agency verifying that the information used to gain marketing authorization remains valid in practice.